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Cardiomyopathy is an inherited or acquired disease of the 
myocardium, which can result in severe ventricular dysfunction. 
Mitochondrial dysfunction is involved in the pathological 
process of cardiomyopathy. Many dysfunctions in cardiac 
mitochondria are consequences of mutations in nuclear or 
mitochondrial DNA followed by alterations in transcriptional 
regulation, mitochondrial protein function, and mitochondrial 
dynamics and energetics, presenting with associated multi-
system mitochondrial disorders. To ensure correct diagnosis 
and optimal management of mitochondrial dysfunction in 
cardiomyopathy caused by multiple pathogenesis, multidisci-
plinary approaches are required, and to integrate between 
clinical and basic sciences, ideal translational models are 
needed. In this review, we will focus on experimental models 
to provide insights into basic mitochondrial physiology and 
detailed underlying mechanisms of cardiomyopathy and current 
mitochondria-targeted therapies for cardiomyopathy. [BMB 
Reports 2015; 48(10): 541-548]
INTRODUCTION
Mitochondrial dysfunction plays a critical role in the under-
lying pathological process of ischemic heart disease (IHD) and 
cardiomyopathy (CM) (1). As a leading cause of death world-
wide (2), IHD (also known as coronary artery disease) is pri-
marily caused by acute myocardial infarction (AMI). A pre-
cursor to heart failure, CM is acutely caused by myocardial is-
chemia and chronically by hypertension or diabetes mellitus. 
Mitochondrial damage occurs primarily during the reperfusion 
phase of ischemia/reperfusion (I/R) (3, 4). In the post-I/R heart, 
mitochondrial dysfunctions are due to inhibition of electron 
transport chain (ETC) function and oxygen (O2) consumption, 
mitochondrial calcium (Ca2＋) overload, reactive oxygen spe-
cies (ROS) generation, mitochondrial permeability transition 
(MPT) pore opening, loss of mitochondrial membrane poten-
tial (Δm), and increased mitochondrial necrosis and apopto-
sis (5-7). Alteration of mitochondrial energy metabolism also 
plays a substantial role in IHD and CM (8). Not surprisingly, 
mitochondria are a potential therapeutic target for IHD and 
CM.
CARDIOMYOPATHY
The heart is composed mostly of the cardiac muscle, or myo-
cardium. Severe or long-standing problems with the cardiac 
muscle can lead to heart failure. Inflammation of the heart is 
called myocarditis, whereas non-inflammatory cardiac muscle 
disease is known as CM, in which the myocardium becomes 
damaged, weakened, or stretched by various causes. Clinically, 
CM is divided into ischemic CM and non-ischemic CM, and in 
turn non-ischemic CM includes three types: dilated (DCM), hy-
pertrophic (HCM), and restrictive (RCM) (9, 10). DCM is charac-
terized by enlargement of the heart and dilated ventricle walls, 
which associated with reduced left ventricle function or sys-
tolic function. In contrast, HCM is characterized by a thick-
ened wall of the left ventricle and/or by a thickened septum 
that separates the left ventricle and the right ventricle. In the 
condition of RCM, the walls of the ventricles become rigid, 
which reduces cardiac output due to diastolic dysfunction. Over 
the past few decades, another type of CM called mitochondrial 
CM has emerged and has been extensively studied. The clinical 
and pathological phenotype of mitochondrial CM, which is pri-
marily found in DCM, HCM, arrhythmias and heart failure, re-
sults from abnormalities in the cardiac mitochondrial oxidative 
phosphorylation (OXPHOS) system, due to genetic defects 
(11).
MITOCHONDRIAL DEFECTS IN EXPERIMENTAL 
MODELS OF CARDIOMYOPATHY
Mitochondrial dysfunction plays a critical role in the patho-
genesis of CM (12, 13). Among various animal models that 
have been established to study the process and mechanisms 
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Modification Species Phenotype Mitochondrial abnormalities Ref.
Transcriptional
regulation
CAPR mtDNA germ-line transmission Mouse DCM Enlarged mitochondria (22)
Tfam cKO Mouse DCM Respiration ↓ (52)
Sirt7 KO Mouse CM Acetylation of GABP1 ↑ (19)
Ncoa6 cKO or DN1 TG Mouse DCM Complex II ↓ (20)
Mitochondrial
protein 
function
Scgd deficient
(BIO 14.6)
Hamster Congenital CM St3 in IFM ↓
Ca2＋ overload
(31)
(95)
Sod2 KO Mouse Neonatal DCM Complex II ↓ (73, 96)
Ant1 KO Mouse HCM Respiration ↓, ROS ↑ (57)
Nix/Bnip3 DKO Mouse CM Accumulation of 
abnormal mitochondria
(37)
CryABR120G mutation Mouse Desmin-related 
CM
Complex I ↓
MPT pore opening ↑
m ↓
(62)
Dystrophin-deficient (mdx) Mouse CM Substrate shift
O2 consumption ↑
(66)
LTCC 2a subunit cTG Mouse CM Ca2＋ overload (67)
MutUNG1 TG Mouse HCM mtDNA stability ↓
Respiration ↓
(21)
Mitochondrial
dynamics
Dnm1lPy/+ Mouse CM ATP ↓ (49)
Mfn1/2 DKO Mouse DCM Mitochondrial fragmentation ↑
Respiration ↓
(39, 42, 43)
Opa1＋/− Mouse CM mtDNA stability ↓
Mitochondrial fragmentation ↑
(44)
Mfn2 KO Mouse DCM O2 consumption ↓
ROS ↑
(40)
(41)
Drp1 cKO Mouse DCM Mitophagy ↑
MPT pore opening ↑
(39)
Induced models DOX-induced model Rabbit
Mouse
Rat
CM ROS ↑ (79)
(78)
(80)
Pacing-induced model Dog DCM Complex I ↓
ROS ↑
(72)
Fz-induced model Turkey
Rat
DCM Mitochondrial swelling ↑
Complex II, IV ↓
m ↓
(68)
(69)
Autoantibodies (M2-AA) Rat DCM-like Mitochondrial swelling ↑ (26)
CAPR: chloramphenicol-resistant, mtDNA: mitochondrial DNA, Tfam: mitochondrial transcription factor A (mtTFA), KO: knock out, cKO: condi-
tional KO, Sirt7: sirtuin 7, GABP1: GA binding protein 1, Ncoa6: nuclear receptor coactivator 6, DN1: dominant-negative mutant containing an 
N-terminal LXXLL-1 motif of NCOA6, TG: transgenic, Scgd: -sarcoglycan, BIO 14.6: Syrian cardiomyopathic hamster, St3: state 3 (ADP-stimu-
lated) respiration, IFM: interfibrillar mitochondria, Sod2: superoxide dismutase 2 (mitochondrial, manganese superoxide dismutase), Ant1: adenine 
nucleotide translocator, ROS: reactive oxygen species, DKO: double KO, CryAB: -B-crystallin, mdx: X chromosome-linked muscular dystrophy, 
LTCC: L-type Ca2＋ channel, mut: mutant, UNG1: uracil-DNA glycosylase 1, Dnm1l: dynamin-1-like, Py: Python (a mouse mutant), Mfn2: mitofu-
sin 2, Opa1: optic atrophy 1, Drp1: dynamin-related protein 1, MPT pore: mitochondrial permeability transition pore, DOX: doxorubicin, Fz: fur-
azolidone, M2-AA: M2 muscarinic receptor, Δm: mitochondrial membrane potential.
Table 1. Experimental models for cardiomyopathy with mitochondrial dysfunction
involved in cardiac disease (14-16), many exhibit CM pheno-
types associated with mitochondrial defects (Table 1).
Transcriptional regulation
As with nuclear DNA (nDNA), mitochondrial DNA (mtDNA) is 
subject to epigenetic modifications related to energetic capacity 
and disease status. When calories are limited, gene expression is 
suppressed due to decreased phosphorylation and acetylation of 
chromatin (17). Sirtuins, or the Silent Information Regulator 2 
(SIR2) protein family includes 7 (Sirt1-7) nicotinamide adenine 
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dinucleotide (NAD＋)-dependent histone deacetylases (HDACs). 
Since sirtuins require NAD＋ for their deacetylase activity, they 
are tightly linked to cellular energy status, such as exercise and 
caloric restriction. Among the 7 isoforms, mitochondrial Sirt3, 
and nuclear Sirt6 and Sirt7 are implicated in left ventricular hy-
pertrophy, CM, and lipid metabolism (18). In Sirt7-deficient 
mice, SIRT7-mediated deacetylation of GA binding protein 1 
(GABP1), a master transcription factor of nDNA-encoded mi-
tochondrial genes, is inhibited. The reduction in deacetylation 
level of GABP1 and the associated transcriptional activity re-
sults in multisystemic mitochondrial dysfunction, including CM 
(19). Recently, we found that either cardiomyocyte-specific abla-
tion of nuclear hormone receptor coactivator (NCOA6) or over-
expression of a dominant-negative mutant form of NCOA6 
(DN1) leads to development of severe DCM with impaired mi-
tochondrial function (20). Ncoa6 deficiency reduces activity of 
peroxisome proliferator-activated receptor  (PPAR ), tran-
scription levels of its target genes, the number of mitochondria 
in cardiomyocytes, and complex II activity (20). However, it is 
still unknown if morphologic and functional abnormalities of 
cardiac mitochondria in Ncoa6 deletion mice are causes or re-
sults of DCM. Cardiomyocyte-specific expression of a mutant ur-
acil-DNA glycosylase 1 (mutUNG1) leads to development of 
HCM, demonstrating that mtDNA toxicity-induced mitochon-
drial dysfunction leads to heart failure. In this transgenic mouse 
heart, increased mitochondrial mass, reduced mtDNA tran-
scription, and suppressed mitochondrial respiration with im-
paired mitochondrial fission and fusion dynamics were ob-
served (21).
Morphologic changes of mitochondria 
The introduction of the mtDNA 16S ribosomal RNA (rRNA) 
chloramphenicol (CAP) resistance mutation into the mouse fe-
male germ line causes CM in chimeric mice. In CAP-resistant 
(CAPR) mouse skeletal muscle and heart, abnormally enlarged 
mitochondria were observed (22). Autoimmunity has been 
considered as one of major causes for idiopathic DCM (23), 
and high titers of autoantibodies (M2-AA) against the second 
extracellular loop of the M2 muscarinic receptor (M2AChR-el2) 
has been found in serum of patients with idiopathic DCM (24). 
Animal models have been established by immunizing rats (25, 
26) or mice (27) with synthetic M2AChR-el2 peptide to induce 
DCM-like morphological changes in the animals’ heart. M2AChR- 
el2-immunized rat heart showed decreased systolic and dia-
stolic function with swollen and damaged mitochondria (26).
Two functionally distinct populations exist in cardiac mi-
tochondria, interfibrillar mitochondria (IFM) and subsarcolemmal 
mitochondria (SSM). IFM is located between the myofibrils, 
whereas SSM is located beneath the plasma membrane. (28). 
Although the coupling of respiration is similar in both pop-
ulations of mitochondria, the rate of substrate oxidation is 
greater in IFM than in SSM (29, 30). Cardiac muscle cells in 
cardiomyopathic hamsters showed depressed oxidation rates 
in IFM, but not in SSM (31).
Dysfunction of mitochondrial dynamics and quality control 
Binding of agonist to G protein-coupled receptor (GPCR) fam-
ily triggers the dissociation of Gq protein into Gq and C 
subunits. GTP-bound Gq (active form) activates phospholipase 
C (PLC) and ultimately protein kinase C (PKC). As activation of 
MAP kinase by Gq has been implicated in stimulating car-
diac growth, transgenically overexpressed Gq in mouse hearts 
causes myocardial hypertrophy with systolic dysfunction and 
DCM with cardiac contractile failure at high-expression levels 
(32). Combined with a pressure overload model by surgical 
transverse aortic constriction (TAC) (33), Gq-mediated my-
ocardial hypertrophy model has been used by the same re-
search group to study roles of pro-apoptotic Bcl-2 family pro-
tein Nix (also known as Bnip3L) and Bnip3 in cardiac hyper-
trophy and apoptotic CM (34-36). Proapoptotic Nix is induced 
in Gq-dependent and pressure overload hypertrophy, and car-
diac-specific expression of Nix triggers apoptotic CM (34). 
Moreover, BNip3/Nix DKO induces the accumulation of ab-
normal mitochondria and causes CM due to mitophagic dys-
function (37).
Mitochondrial dynamics, mitochondrial fission and fusion, 
are involved in the mechanisms of a variety of human diseases 
including cancer, neurodegenerative diseases, and cardiovascular 
diseases (38). Dorn and his associates have intensively studied 
the connection between mitochondrial dynamics and CM 
(39-44). Using genetic ablations of the pro-fission factor dyna-
min-related protein 1 (Drp1) and the pro-fusion factors mitofu-
sins (Mfn1, Mfn2, and Mfn1/2) and optic atrophy 1 (Opa1), 
they demonstrated that mitochondrial fission and fusion dyna-
mism plays an important role in pathophysiology of CM and 
heart failure (45). Mitophagy, the autophagy of mitochondria, is 
a selective clearance process of damaged or aged mitochondria 
(46, 47). Regulation of mitophagy requires two Parkinson’s dis-
ease factors, the mitochondrial kinase PINK1 (PTEN-induced 
putative kinase protein 1) and the cytosolic ubiquitin ligase 
Parkin (48). Mfn2-deficient mouse cardiomyocytes exhibited 
accumulation of morphologically and functionally abnormal 
mitochondria due to suppressed mitophagy and subsequent re-
duction of oxygen (O2) consumption, suggesting that the mi-
tochondrial respiratory impairment contributes to the develop-
ment of DCM (40). Interrupting mitochondrial fusion by com-
bined Mfn1/Mfn2 ablation in adult hearts increased mitochon-
drial fragmentation and induced mitochondrial respiratory dys-
function, causing lethal DCM (39, 42, 43). Since the homo-
zygous mutation is embryonic lethal, heterozygous Opa＋/− 
mice were generated and examined. Abnormal cardiac func-
tion with reduced mtDNA stability and fragmented mitochon-
dria was observed in aged Opa＋/− mouse heart, which devel-
ops late-onset CM (44). In contrast, cardiomyocyte-specific 
Drp1 knock out (KO) mice showing increased cardiomyocyte 
mitophagy and mitochondrial permeability transition (MPT) 
pore opening, led to cardiomyocyte necrosis and DCM (39). A 
mutation in another mitochondrial fission gene Dnm1l 
(Dnm1lPy/＋) also led to CM. ATP depletion observed in 
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Dnm1lPy/＋ mouse heart possibly contributes to CM (49). These 
studies suggest that the cardiac mitochondrial quality control 
process is critical in pathophysiology of CM.
Impaired mitochondrial metabolism 
Transcription of mtDNA is controlled by nuclear gene-encoded 
regulatory proteins such as mitochondrial transcription factor A 
(Tfam, also known as mtTFA) (50, 51). Mutant animals, whose 
Tfam gene is disrupted in heart and muscle, developed DCM 
similar to Kearns-Sayre syndrome due to cardiac-specific inacti-
vation of mtDNA gene expression (52) and cardiac respiratory 
chain dysfunction (53). The main function of mitochondria in 
the cardiac muscle is ATP synthesis via the OXPHOS system. 
Reducing equivalents, such as the reduced form of nicotina-
mide adenine dinucleotide (NADH) and flavin adenine dinu-
cleotide (FADH2) generated by the tricarboxylic acid (TCA) cy-
cle following substrate oxidation (fatty acids or glucose), are 
used by the respiratory chain to produce an electrochemical 
gradient across the mitochondrial membrane [mitochondrial 
membrane potential (Δm)] that drives ATP synthesis. In the 
adult myocardium, although both fatty acids and glucose are 
utilized, fatty acids are preferentially oxidized, supplying ap-
proximately 70% of total ATP (54, 97). In the failing heart, oxi-
dation of carbohydrate substrates (glucose and lactate) is im-
paired and fatty acid oxidation (FAO) is enhanced (55). Heart 
failure patients may benefit from increasing oxidation of pyr-
uvate which derives glucose and lactate, by pharmacologically 
activating pyruvate dehydrogenase (PDH) (56) (see section 
Mitochondria as a Therapeutic Target for Cardiomyopathy). 
Conditional KO mice of adenine nucleotide translocator (Ant1) 
revealed a dramatic proliferation of mitochondria and cardiac 
hypertrophy. As Ant1 KO also has the metabolic acidosis phe-
notype and its isolated mitochondria exhibited a severe defect 
in coupled respiration, it will be a good animal model to study 
all the biochemical, histological, metabolic and physiological 
characteristics of mitochondrial myopathy and CM (57). 
Desmin-related CM is caused by mutations in desmin, -B-crys-
tallin (CryAB), and other genes (58, 59). In particular an R120G 
missense mutation in CryAB results in desmin-related CM (60). 
Although desmin-related CM caused by mutations in desmin is 
not associated with mitochondria (61), a mouse model of des-
min-related CM caused by CryABR120G showed that reduced 
complex I activity with alterations in the MPT pore and mi-
tochondrial membrane potential (Δm) eventually resulted in 
cardiac cell death, CM, and heart failure (62). Since deficiencies 
in the cytoskeletal protein dystrophin have been implicated in 
the pathogenesis of both genetic and acquired forms of CM 
(63-65), the dystrophin-deficient mdx mouse is considered a 
good experimental model for CM. In the mdx mouse heart, a 
marked shift in substrate from fatty acids to carbohydrates asso-
ciated with enhanced oxygen consumption was observed (66). 
Overexpression of the LTCC 2a subunit enhanced Ca2＋ in-
flux-induced cellular necrosis and induced CM, supporting the 
concept that necrosis associated with Ca2＋ overload can also 
contribute to loss of cardiomyocytes in heart failure (67). 
Furazolidone (Fz), a nitrofuran antibacterial, used to establish a 
turkey model of DCM, with similarities to DCM in human (68), 
was also used to establish a rat model of DCM (69). The Fz-in-
duced rat model heart showed significant myocardial degener-
ation and mitochondrial swelling with decreases in mitochon-
drial membrane potential (Δm) and activities of complex II 
and IV (69).
Together with small animal models, large animal models are 
needed to translate discoveries from the basic sciences into 
clinical applications. The pacing-induced DCM model is ob-
tained by continuous cardiac pacing at a higher frequency 
than the spontaneous heart rate in dogs, pigs, sheep and mon-
keys (70, 71). In a pacing-induced canine model of DCM, de-
creases in the enzymatic activity of complex I were observed 
(72).
Increased oxidative stress 
Superoxide dismutase 2 (SOD2, also known as mitochondrial 
MnSOD) mutant mice developed a neonatal CM, indicating 
that mitochondrial ROS can cause accumulation of oxidative 
DNA damage (73). As described in the section Dysfunction of 
Mitochondrial dynamics and quality control, due to impaired 
Parkin-mediated mitophagy, Mfn2 KO hearts exhibit accumu-
lation of damaged mitochondria, which produces ROS. Cardio-
myocyte-specific expression of mitochondrial-targeted catalase 
reversed ROS-mediated dysfunction of mitochondrial quality 
control mechanisms in Mfn2 KO hearts (41). Mutation of the 
Ant1 gene also increases mitochondrial ROS production (57). 
The most effective anti-cancer drug, doxorubicin (DOX), has 
been reported to have cardiotoxicity (74, 75) and thus DOX-in-
duced CM has been considered a good model for studying con-
gestive heart failure induced by anthracycline analogues (76, 
77). Various DOX-induced CM animal models have been de-
veloped in mouse (78), rabbit (79), and rat (80). The increased 
superoxide production in pacing-induced canine model of 
DCM and heart failure suggested that complex I is a potential 
source of mitochondrial production of ROS in failing hearts 
(72). All these reports provide important insights into the role of 
mitochondrial ROS in the pathophysiology of CM.
MITOCHONDRIA AS A THERAPEUTIC TARGET FOR 
CARDIOMYOPATHY
The development of experimental models of mitochondrial 
heart diseases also provides the opportunity to investigate the 
efficacy of new mitochondria-targeting drugs and their under-
lying mechanisms of action. Many studies have targeted bio-
energetic dysfunction of mitochondria by adding cofactors, 
such as coenzyme Q or L-carnitine to therapies for treatment 
of heart failure associated with CM (81, 82). Coenzyme Q10 
(also known as ubiquinone) functions as an antioxidant and its 
deficiency is associated with CM (83). The coenzyme Q ana-
log idebenone corrects cardiac diastolic dysfunction and im-
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proves exercise performance in the mdx mouse model of 
Duchenne muscular dystrophy (DMD) (84). Although initial 
trials have shown some benefits in preventing progression of 
HCM, recent controlled trials reported that idebenone neither 
decreased left ventricular hypertrophy nor improved cardiac 
function in patients with Friedreich’s ataxia (FRDA) (81, 85). 
Long-term administration of L-carnitine for the treatment of HF 
caused by DCM showed improved survival (86). The carnitine 
palmitoyltransferase 1 (CPT-I) inhibitor, perhexilin, corrected 
energy deficiency caused by diastolic dysfunction and im-
proved exercise capacity in HCM patients, suggesting its func-
tion as a metabolic modulator (shifting FAO to glucose oxida-
tion) (87). Another CPT-I inhibitor, oxfenicine showed similar 
effects in dog heart, in which CPT-I inhibition prevents ven-
tricular remodeling (88). Dichloroacetate (DCA) is another po-
tential therapy for CM, by stimulating pyruvate dehydrogenase 
is stimulated to drive pyruvate to mitochondrial OXPHOS, in-
creasing acetyl-CoA and NADH levels. However, treatment of 
non-ischemic and ischemic DCM patients with DCA showed 
inconsistent effects on left ventricular mechanical efficiency 
and myocardial O2 consumption (89, 90). L-arginine has also 
been proposed as a treatment for CM. In patients with mi-
tochondrial CM, L-arginine enhanced aerobic metabolism and 
myocardial efficiency, independent of its vasodilation effect 
(91). Because the primary target of DOX-induced CM is the 
mitochondria, in which DOX triggers the generation of ROS 
and lipid peroxidation (76, 77), numerous studies have tested 
iron-chelating agents [e.g., dexrazoxane (92)], antioxidants 
[e.g., MnTBAP and ebselen (93)], and the phosphodiesterase 5 
inhibitor sildenafil (94) to prevent the mitochondrial dysfunc-
tions in DOX-induced CM.
CONCLUDING REMARKS
Mitochondrial dysfunction is substantially involved in arrhyth-
mogenic cardiac diseases, including inherited and acquired 
CM. Alterations in mitochondrial morphology, impaired en-
ergy production (i.e. ATP synthesis) and enhanced pathologic 
function (i.e. ROS generation, Ca2＋ overload and apoptosis) 
cause cardiomyocyte injury and/or cell death due to malfunc-
tion of cellular mechanisms involved in maintaining intra-
cellular Ca2＋ homeostasis and normal mechanical and elec-
trical functions of heart.
Although interpretations must be made with appropriate 
caution, i.e. “a man will never be a mouse”, studies of mi-
tochondrial function in cardiac disease using animal models 
will undoubtedly continue to provide new insights into the 
mechanisms of cardiac mitochondrial damage and a better un-
derstanding of the mitochondrial-mediated injury pathways in-
volved in CM and heart failure. Current pharmacologic strat-
egies have not yet been proven effective, and large random-
ized controlled trials are needed to establish a link between 
mitochondria and CM. Cross-disciplinary analysis will hope-
fully provide unique insights into mitochondrial disorders and 
optimum translational models with which to challenge our 
perspectives on human CM and heart failure while also sug-
gesting new therapeutic strategies.
ACKNOWLEDGEMENTS
This work was supported by the Basic Science Research Program 
through the National Research Foundation of Korea (NRF) fund-
ed by the Ministry of Education (NRF-2014R1A2A1A11052412).
REFERENCES
1. Walters AM, Porter GA Jr. and Brookes PS (2012) Mito-
chondria as a drug target in ischemic heart disease and 
cardiomyopathy. Circ Res 111, 1222-1236
2. Roger VL, Go AS, Lloyd-Jones DM et al (2012) Heart dis-
ease and stroke statistics--2012 update: a report from the 
American Heart Association. Circulation 125, e2-e220
3. Ambrosio G, Zweier JL, Duilio C et al (1993) Evidence 
that mitochondrial respiration is a source of potentially 
toxic oxygen free radicals in intact rabbit hearts subjected 
to ischemia and reflow. J Biol Chem 268, 18532-18541
4. Lucas DT and Szweda LI (1998) Cardiac reperfusion in-
jury: aging, lipid peroxidation, and mitochondrial dys-
function. Proc Natl Acad Sci U S A 95, 510-514
5. Murphy E and Steenbergen C (2008) Mechanisms under-
lying acute protection from cardiac ischemia-reperfusion 
injury. Physiol Rev 88, 581-609
6. Brenner C and Moulin M (2012) Physiological roles of the 
permeability transition pore. Circ Res 111, 1237-1247
7. Kwong JQ and Molkentin JD (2015) Physiological and 
pathological roles of the mitochondrial permeability tran-
sition pore in the heart. Cell Metab 21, 206-214
8. Huss JM and Kelly DP (2005) Mitochondrial energy me-
tabolism in heart failure: a question of balance. J Clin 
Invest 115, 547-555
9. Towbin JA and Bowles NE (2002) The failing heart. 
Nature 415, 227-233
10. Cecchi F, Tomberli B and Olivotto I (2012) Clinical and 
molecular classification of cardiomyopathies. Glob Cardiol 
Sci Pract 2012, 4
11. Ozawa T (1994) Mitochondrial cardiomyopathy. Herz 19, 
105-118, 125
12. Stanley WC and Hoppel CL (2000) Mitochondrial dys-
function in heart failure: potential for therapeutic inter-
ventions? Cardiovasc Res 45, 805-806
13. Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J and 
Hoppel CL (2001) Mitochondrial dysfunction in cardiac 
disease: ischemia--reperfusion, aging, and heart failure. J 
Mol Cell Cardiol 33, 1065-1089
14. Ikeda Y and Ross J Jr. (2000) Models of dilated cardiomy-
opathy in the mouse and the hamster. Curr Opin Cardiol 
15, 197-201
15. Benjamin IJ and Schneider MD (2005) Learning from fail-
ure: congestive heart failure in the postgenomic age. J Clin 
Invest 115, 495-499
16. Recchia FA and Lionetti V (2007) Animal models of di-
lated cardiomyopathy for translational research. Vet Res 
An experimental approach to study the function of mitochondria in cardiomyopathy
Youn Wook Chung and Seok-Min Kang
546 BMB Reports http://bmbreports.org
Commun 31 Suppl 1, 35-41
17. Wallace DC and Fan W (2010) Energetics, epigenetics, 
mitochondrial genetics. Mitochondrion 10, 12-31
18. Winnik S, Auwerx J, Sinclair DA and Matter CM (2015) 
Protective effects of sirtuins in cardiovascular diseases: 
from bench to bedside. Eur Heart J  [Epub ahead of print]
19. Ryu D, Jo YS, Lo Sasso G et al (2014) A SIRT7-dependent 
acetylation switch of GABPbeta1 controls mitochondrial 
function. Cell Metab 20, 856-869
20. Roh JI, Cheong C, Sung YH et al (2014) Perturbation of 
NCOA6 leads to dilated cardiomyopathy. Cell Rep 8, 
991-998
21. Lauritzen KH, Kleppa L, Aronsen JM et al (2015) Im-
paired dynamics and function of mitochondria caused by 
mtDNA toxicity leads to heart failure. Am J Physiol Heart 
Circ Physiol 309, H434-449
22. Sligh JE, Levy SE, Waymire KG et al (2000) Maternal 
germ-line transmission of mutant mtDNAs from embry-
onic stem cell-derived chimeric mice. Proc Natl Acad Sci 
U S A 97, 14461-14466
23. Baba A, Yoshikawa T, Fukuda Y et al (2004) Autoantibodies 
against M2-muscarinic acetylcholine receptors: new up-
stream targets in atrial fibrillation in patients with dilated 
cardiomyopathy. Eur Heart J 25, 1108-1115
24. Fu LX, Magnusson Y, Bergh CH et al (1993) Localization 
of a functional autoimmune epitope on the muscarinic 
acetylcholine receptor-2 in patients with idiopathic dilated 
cardiomyopathy. J Clin Invest 91, 1964-1968
25. Fu ML, Schulze W, Wallukat G, Hjalmarson A and 
Hoebeke J (1995) Functional epitope analysis of the sec-
ond extracellular loop of the human heart muscarinic ace-
tylcholine receptor. J Mol Cell Cardiol 27, 427-436
26. Zhang S, He Z, Wang J et al (2015) Mitochondrial 
Ultrastructural Alterations and Declined M2 Receptor 
Density Were Involved in Cardiac Dysfunction in Rats af-
ter Long Term Treatment with Autoantibodies against M2 
Muscarinic Receptor. PLoS One 10, e0129563
27. Yoshizawa A, Nagai S, Baba Y et al (2012) Autoimmunity 
against M(2)muscarinic acetylcholine receptor induces 
myocarditis and leads to a dilated cardiomyopathy-like 
phenotype. Eur J Immunol 42, 1152-1163
28. Palmer JW, Tandler B and Hoppel CL (1977) Biochemical 
properties of subsarcolemmal and interfibrillar mitochon-
dria isolated from rat cardiac muscle. J Biol Chem 252, 
8731-8739
29. Shin G, Sugiyama M, Shoji T, Kagiyama A, Sato H and 
Ogura R (1989) Detection of mitochondrial membrane 
damages in myocardial ischemia with ESR spin labeling 
technique. J Mol Cell Cardiol 21, 1029-1036
30. Palmer JW, Tandler B and Hoppel CL (1985) Biochemical 
differences between subsarcolemmal and interfibrillar mi-
tochondria from rat cardiac muscle: effects of procedural 
manipulations. Arch Biochem Biophys 236, 691-702
31. Hoppel CL, Tandler B, Parland W, Turkaly JS and Albers 
LD (1982) Hamster cardiomyopathy. A defect in oxidative 
phosphorylation in the cardiac interfibrillar mitochondria. 
J Biol Chem 257, 1540-1548
32. D'Angelo DD, Sakata Y, Lorenz JN et al (1997) Transgenic 
Galphaq overexpression induces cardiac contractile fail-
ure in mice. Proc Natl Acad Sci U S A 94, 8121-8126
33. Sakata Y, Hoit BD, Liggett SB, Walsh RA and Dorn GW 
2nd (1998) Decompensation of pressure-overload hyper-
trophy in G alpha q-overexpressing mice. Circulation 97, 
1488-1495
34. Yussman MG, Toyokawa T, Odley A et al (2002) Mito-
chondrial death protein Nix is induced in cardiac hyper-
trophy and triggers apoptotic cardiomyopathy. Nat Med 8, 
725-730
35. Syed F, Odley A, Hahn HS et al (2004) Physiological 
growth synergizes with pathological genes in experimental 
cardiomyopathy. Circ Res 95, 1200-1206
36. Diwan A, Wansapura J, Syed FM, Matkovich SJ, Lorenz JN 
and Dorn GW 2nd (2008) Nix-mediated apoptosis links 
myocardial fibrosis, cardiac remodeling, and hypertrophy 
decompensation. Circulation 117, 396-404
37. Dorn GW 2nd (2010) Mitochondrial pruning by Nix and 
BNip3: an essential function for cardiac-expressed death 
factors. J Cardiovasc Transl Res 3, 374-383
38. Archer SL (2013) Mitochondrial dynamics--mitochondrial 
fission and fusion in human diseases. N Engl J Med 369, 
2236-2251
39. Song M, Mihara K, Chen Y, Scorrano L and Dorn GW 2nd 
(2015) Mitochondrial fission and fusion factors recip-
rocally orchestrate mitophagic culling in mouse hearts 
and cultured fibroblasts. Cell Metab 21, 273-285
40. Chen Y and Dorn GW 2nd (2013) PINK1-phosphorylated 
mitofusin 2 is a Parkin receptor for culling damaged mito-
chondria. Science 340, 471-475
41. Song M, Chen Y, Gong G, Murphy E, Rabinovitch PS and 
Dorn GW 2nd (2014) Super-suppression of mitochondrial 
reactive oxygen species signaling impairs compensatory 
autophagy in primary mitophagic cardiomyopathy. Circ 
Res 115, 348-353
42. Chen Y, Liu Y and Dorn GW 2nd (2011) Mitochondrial 
fusion is essential for organelle function and cardiac ho-
meostasis. Circ Res 109, 1327-1331
43. Papanicolaou KN, Kikuchi R, Ngoh GA et al (2012) 
Mitofusins 1 and 2 are essential for postnatal metabolic re-
modeling in heart. Circ Res 111, 1012-1026
44. Chen L, Liu T, Tran A et al (2012) OPA1 mutation and 
late-onset cardiomyopathy: mitochondrial dysfunction 
and mtDNA instability. J Am Heart Assoc 1, e003012
45. Song M and Dorn GW 2nd (2015) Mitoconfusion: non-
canonical functioning of dynamism factors in static mi-
tochondria of the heart. Cell Metab 21, 195-205
46. Kubli DA and Gustafsson AB (2012) Mitochondria and mi-
tophagy: the yin and yang of cell death control. Circ Res 
111, 1208-1221
47. Delbridge LM, Mellor KM, Taylor DJ and Gottlieb RA 
(2015) Myocardial autophagic energy stress responses-- 
macroautophagy, mitophagy, and glycophagy. Am J Physiol 
Heart Circ Physiol 308, H1194-1204
48. Shirihai OS, Song M and Dorn GW 2nd (2015) How 
Mitochondrial Dynamism Orchestrates Mitophagy. Circ 
Res 116, 1835-1849
49. Ashrafian H, Docherty L, Leo V et al (2010) A mutation in 
the mitochondrial fission gene Dnm1l leads to cardiomyo-
pathy. PLoS Genet 6, e1001000
50. Gray MW, Burger G and Lang BF (1999) Mitochondrial 
evolution. Science 283, 1476-1481
An experimental approach to study the function of mitochondria in cardiomyopathy
Youn Wook Chung and Seok-Min Kang
547http://bmbreports.org BMB Reports
51. Fosslien E (2003) Review: Mitochondrial medicine--car-
diomyopathy caused by defective oxidative phosphoryla-
tion. Ann Clin Lab Sci 33, 371-395
52. Wang J, Wilhelmsson H, Graff C et al (1999) Dilated car-
diomyopathy and atrioventricular conduction blocks in-
duced by heart-specific inactivation of mitochondrial DNA 
gene expression. Nat Genet 21, 133-137
53. Li H, Wang J, Wilhelmsson H et al (2000) Genetic mod-
ification of survival in tissue-specific knockout mice with 
mitochondrial cardiomyopathy. Proc Natl Acad Sci U S A 
97, 3467-3472
54. Wisneski JA, Gertz EW, Neese RA and Mayr M (1987) 
Myocardial metabolism of free fatty acids. Studies with 
14C-labeled substrates in humans. J Clin Invest 79, 359- 
366
55. Stanley WC and Chandler MP (2002) Energy metabolism 
in the normal and failing heart: potential for therapeutic 
interventions. Heart Fail Rev 7, 115-130
56. Stanley WC, Lopaschuk GD, Hall JL and McCormack JG 
(1997) Regulation of myocardial carbohydrate metabolism 
under normal and ischaemic conditions. Potential for 
pharmacological interventions. Cardiovasc Res 33, 243-257
57. Graham BH, Waymire KG, Cottrell B, Trounce IA, Mac-
Gregor GR and Wallace DC (1997) A mouse model for 
mitochondrial myopathy and cardiomyopathy resulting 
from a deficiency in the heart/muscle isoform of the ad-
enine nucleotide translocator. Nat Genet 16, 226-234
58. Engel AG (1999) Myofibrillar myopathy. Ann Neurol 46, 
681-683
59. Paulin D, Huet A, Khanamyrian L and Xue Z (2004) 
Desminopathies in muscle disease. J Pathol 204, 418-427
60. Vicart P, Caron A, Guicheney P et al (1998) A missense 
mutation in the alphaB-crystallin chaperone gene causes a 
desmin-related myopathy. Nat Genet 20, 92-95
61. Wang X, Osinska H, Dorn GW 2nd et al (2001) Mouse 
model of desmin-related cardiomyopathy. Circulation 103, 
2402-2407
62. Maloyan A, Sanbe A, Osinska H et al (2005) Mitochon-
drial dysfunction and apoptosis underlie the pathogenic 
process in alpha-B-crystallin desmin-related cardiomyopa-
thy. Circulation 112, 3451-3461
63. Badorff C, Lee GH, Lamphear BJ et al (1999) Enteroviral 
protease 2A cleaves dystrophin: evidence of cytoskeletal 
disruption in an acquired cardiomyopathy. Nat Med 5, 
320-326
64. Feng J, Yan J, Buzin CH, Towbin JA and Sommer SS 
(2002) Mutations in the dystrophin gene are associated 
with sporadic dilated cardiomyopathy. Mol Genet Metab 
77, 119-126
65. Vatta M, Stetson SJ, Perez-Verdia A et al (2002) Molecular 
remodelling of dystrophin in patients with end-stage car-
diomyopathies and reversal in patients on assistance-de-
vice therapy. Lancet 359, 936-941
66. Khairallah M, Khairallah R, Young ME, Dyck JR, Petrof BJ 
and Des Rosiers C (2007) Metabolic and signaling alter-
ations in dystrophin-deficient hearts precede overt cardio-
myopathy. J Mol Cell Cardiol 43, 119-129
67. Nakayama H, Chen X, Baines CP et al (2007) Ca2+- and 
mitochondrial-dependent cardiomyocyte necrosis as a pri-
mary mediator of heart failure. J Clin Invest 117, 2431-2444
68. Hajjar RJ, Liao R, Young JB, Fuleihan F, Glass MG and 
Gwathmey JK (1993) Pathophysiological and biochemical 
characterisation of an avian model of dilated cardiomyop-
athy: comparison to findings in human dilated cardiomyo-
pathy. Cardiovasc Res 27, 2212-2221
69. Zhang M, Wei J, Shan H et al (2013) Calreticulin-STAT3 
signaling pathway modulates mitochondrial function in a 
rat model of furazolidone-induced dilated cardiomyopathy. 
PLoS One 8, e66779
70. Armstrong PW, Stopps TP, Ford SE and de Bold AJ (1986) 
Rapid ventricular pacing in the dog: pathophysiologic 
studies of heart failure. Circulation 74, 1075-1084
71. Spinale FG, Hendrick DA, Crawford FA, Smith AC, 
Hamada Y and Carabello BA (1990) Chronic supraven-
tricular tachycardia causes ventricular dysfunction and 
subendocardial injury in swine. Am J Physiol 259, H218- 
229
72. Ide T, Tsutsui H, Kinugawa S et al (1999) Mitochondrial 
electron transport complex I is a potential source of oxy-
gen free radicals in the failing myocardium. Circ Res 85, 
357-363
73. Melov S, Coskun P, Patel M et al (1999) Mitochondrial 
disease in superoxide dismutase 2 mutant mice. Proc Natl 
Acad Sci U S A 96, 846-851
74. Lefrak EA, Pitha J, Rosenheim S and Gottlieb JA (1973) A 
clinicopathologic analysis of adriamycin cardiotoxicity. 
Cancer 32, 302-314
75. Gilladoga AC, Manuel C, Tan CT, Wollner N, Sternberg 
SS and Murphy ML (1976) The cardiotoxicity of adriamy-
cin and daunomycin in children. Cancer 37, 1070-1078
76. Takemura G and Fujiwara H (2007) Doxorubicin-induced 
cardiomyopathy from the cardiotoxic mechanisms to ma-
nagement. Prog Cardiovasc Dis 49, 330-352
77. Sawyer DB (2013) Anthracyclines and heart failure. N 
Engl J Med 368, 1154-1156
78. van der Vijgh WJ, van Velzen D, van der Poort JS et al 
(1988) Morphometric study of myocardial changes during 
doxorubicin-induced cardiomyopathy in mice. Eur J 
Cancer Clin Oncol 24, 1603-1608
79. Shenasa H, Calderone A, Vermeulen M et al (1990) 
Chronic doxorubicin induced cardiomyopathy in rabbits: 
mechanical, intracellular action potential, and beta adre-
nergic characteristics of the failing myocardium. Cardiovasc 
Res 24, 591-604
80. Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J and 
Walker UA (2003) Time-dependent and tissue-specific ac-
cumulation of mtDNA and respiratory chain defects in 
chronic doxorubicin cardiomyopathy. Circulation 108, 
2423-2429
81. Kerr DS (2010) Treatment of mitochondrial electron trans-
port chain disorders: a review of clinical trials over the 
past decade. Mol Genet Metab 99, 246-255
82. Gurlek A, Tutar E, Akcil E et al (2000) The effects of L-car-
nitine treatment on left ventricular function and eryth-
rocyte superoxide dismutase activity in patients with is-
chemic cardiomyopathy. Eur J Heart Fail 2, 189-193
83. Singh RB, Niaz MA, Rastogi V and Rastogi SS (1998) 
Coenzyme Q in cardiovascular disease. J Assoc Physicians 
India 46, 299-306
84. Buyse GM, Van der Mieren G, Erb M et al (2009) Long- 
An experimental approach to study the function of mitochondria in cardiomyopathy
Youn Wook Chung and Seok-Min Kang
548 BMB Reports http://bmbreports.org
term blinded placebo-controlled study of SNT-MC17/ide-
benone in the dystrophin deficient mdx mouse: cardiac 
protection and improved exercise performance. Eur Heart 
J 30, 116-124
85. Lagedrost SJ, Sutton MS, Cohen MS et al (2011) Idebenone 
in Friedreich ataxia cardiomyopathy-results from a 6-month 
phase III study (IONIA). Am Heart J 161, 639-645 e631
86. Rizos I (2000) Three-year survival of patients with heart 
failure caused by dilated cardiomyopathy and L-carnitine 
administration. Am Heart J 139, S120-123
87. Abozguia K, Elliott P, McKenna W et al (2010) Metabolic 
modulator perhexiline corrects energy deficiency and im-
proves exercise capacity in symptomatic hypertrophic car-
diomyopathy. Circulation 122, 1562-1569
88. Lionetti V, Linke A, Chandler MP et al (2005) Carnitine 
palmitoyl transferase-I inhibition prevents ventricular re-
modeling and delays decompensation in pacing-induced 
heart failure. Cardiovasc Res 66, 454-461
89. Bersin RM, Wolfe C, Kwasman M et al (1994) Improved 
hemodynamic function and mechanical efficiency in con-
gestive heart failure with sodium dichloroacetate. J Am 
Coll Cardiol 23, 1617-1624
90. Lewis JF, DaCosta M, Wargowich T and Stacpoole P 
(1998) Effects of dichloroacetate in patients with con-
gestive heart failure. Clin Cardiol 21, 888-892
91. Arakawa K, Kudo T, Ikawa M et al (2010) Abnormal my-
ocardial energy-production state in mitochondrial car-
diomyopathy and acute response to L-arginine infusion. 
C-11 acetate kinetics revealed by positron emission 
tomography. Circ J 74, 2702-2711
92. Lebrecht D, Geist A, Ketelsen UP, Haberstroh J, Setzer B 
and Walker UA (2007) Dexrazoxane prevents doxorubi-
cin-induced long-term cardiotoxicity and protects my-
ocardial mitochondria from genetic and functional lesions 
in rats. Br J Pharmacol 151, 771-778
93. Konorev EA, Kennedy MC and Kalyanaraman B (1999) 
Cell-permeable superoxide dismutase and glutathione per-
oxidase mimetics afford superior protection against doxor-
ubicin-induced cardiotoxicity: the role of reactive oxygen 
and nitrogen intermediates. Arch Biochem Biophys 368, 
421-428
94. Fisher PW, Salloum F, Das A, Hyder H and Kukreja RC 
(2005) Phosphodiesterase-5 inhibition with sildenafil at-
tenuates cardiomyocyte apoptosis and left ventricular dys-
function in a chronic model of doxorubicin cardiotoxicity. 
Circulation 111, 1601-1610
95. Wagner JA, Weisman HF, Snowman AM, Reynolds IJ, 
Weisfeldt ML and Snyder SH (1989) Alterations in cal-
cium antagonist receptors and sodium-calcium exchange 
in cardiomyopathic hamster tissues. Circ Res 65, 205-214
96. Li Y, Huang TT, Carlson EJ et al (1995) Dilated cardiomy-
opathy and neonatal lethality in mutant mice lacking man-
ganese superoxide dismutase. Nat Genet 11, 376-381
97. Shipp JC, Opie LH and Challoner D (1961) Fatty acid and 
glucose metabolism in the perfused heart. Nature 189, 
1018-1019
